Piñeiro Alonso, LauraRubio Prego, InésLobyntseva, AlexandraGonzález Freire, EvaLanger, RobertAlonso Fernández, María José2025-11-282025-11-282025-05-16Pineiro-Alonso, L., Rubio-Prego, I., Lobyntseva, A., González-Freire, E., Langer, R., & Alonso, M. J. (2025). Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations. Advanced Drug Delivery Reviews, 222, 115606. 10.1016/j.addr.2025.1156060169-409Xhttps://hdl.handle.net/10347/44075The development of novel therapies for central nervous system (CNS) diseases, particularly neurodegenerative disorders like Alzheimer’s disease (AD), is a critical global health priority. Biotherapeutics, such as monoclonal antibodies (mAbs) and RNA-based therapies, have shown potential for treating brain disorders. However, their clinical progress is limited by their difficult access to their brain targets. At the preclinical level, nanotechnology has been shown, to help these molecules overcome the biological barriers that imped their adequate brain delivery. This review highlights advances in this area and the challenges for the translation to the clinic. Key nanotechnology-based strategies, such as surface modifications utilizing endogenous protein corona, functionalization with targeting ligands, therapeutic ultrasound-mediated microbubble oscillation were particularly analyzed. Additionally, in line with the focus of the Special Issue, this review integrates the concept of chronotherapy, with a focus on AD treatment, highlighting the idea that, by aligning nanoparticle (NP)-based drug delivery with circadian rhythms, it may be possible to improve therapeutic outcomes. Finally, the article analyzes current strategies in CNS drug delivery in clinical trials and provides future directions within this frame, notably in the area of AD.eng© 2025 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Brain BBBNanotechnologyAlzheimer’s diseaseChronotherapyRNAMonoclonal antibodyjournal article10.1016/j.addr.2025.115606open access